Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 8/20 | 0.39 |
| ▸ | DRD2 | P14416 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14818994 | 0.95 | POLB (0.50) | POLBKDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL9355210 | 0.91 | POLB (0.57) | POLBKDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10223283 | 0.86 | POLB (0.44) | POLBKDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL18622113 | 0.85 | POLB (0.57) | POLBKDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10633351 | 0.83 | MEN1 (0.58) | POLBKDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14960444 | 0.81 | RIPK1 (0.43) | POLBALDH1A1SMN1; SMN2CA3CA5A | |
| SCHEMBL25942505 | 0.80 | POLB (0.49) | POLBKDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4147505 | 0.80 | ALDH1A1 (0.71) | POLBKDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16316312 | 0.80 | POLB (0.50) | POLBKDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12264270 | 0.79 | PGK1 (0.46) | POLBALDH1A1SMN1; SMN2CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| WO-2022264069-A1 | METHOD FOR PREPARING FLUOROPHORE- AND CHROMOPHORE-CONTAINING CONJUGATES FOR VISUAL DETECTION OF ANALYTE MOLECULES | Sony Group Corporation (JP) | 2022-12-22 | — | — | WO | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | POLB 1569/4885KDM4E 2608/4885MAPT 2472/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | POLB 2088/4885KDM4E 190/4885MAPT 2459/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | POLB 2088/4885KDM4E 190/4885MAPT 2459/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | POLB 1991/4885KDM4E 2269/4885MAPT 2572/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | POLB 2088/4885KDM4E 190/4885MAPT 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.